Showing 6271-6280 of 19379 results for "".
Real-World Cases in Pediatric Low-Grade Glioma: Exploring Targeted Therapies
https://reachmd.com/programs/project-oncology/real-world-cases-in-pediatric-low-grade-glioma/37197/What’s guiding today’s treatment decisions for patients with pediatric low-grade glioma? Find out with Dr. Alexandria May as she speaks with Drs. Angela Waanders and Ashley Margol. Together, they examine real-world patient cases that highlight evolving approaches to care, including targeted therapieEvaluating the Efficacy of Zuranolone for Postpartum Depression
https://reachmd.com/programs/advances-in-womens-health/evaluating-the-efficacy-of-zuranolone-for-postpartum-depression/32752/Zuranolone is the first oral drug approved by the FDA for the treatment of postpartum depression. Based on a recent systemic review and meta-analysis, it could provide rapid relief from symptoms within two weeks. Here to discuss the study’s findings and the potential impacts for patients suffering fOptimizing Medical Affairs Approaches with CME Best Practices
https://reachmd.com/programs/maps-chats/medical-affairs-cme-best-practices/56815/For medical affairs teams, demonstrating the value and impact of educational initiatives in a meaningful and measurable way is essential. At the 2026 Medical Affairs Professional Society (MAPS) Annual Meeting, Dr. Matt Birnholz spoke with Ms. Karen Roy, CEO and Co-Founder of Infograph-ed, about howDiagnosing Psoriatic Arthritis: A Real-World Case
https://reachmd.com/programs/living-rheum/diagnosing-psoriatic-arthritis-a-real-world-case/56347/Diagnosing psoriatic arthritis can be challenging, particularly when skin findings are subtle or hidden. In this case-based discussion, Dr. Lawrence H. Brent highlights key clinical clues and examination strategies from his own practice that can help clinicians identify psoriatic disease earlier andExpanding Molecular Testing in Community NSCLC Care
https://reachmd.com/programs/project-oncology/molecular-testing-community-nsclc-care/54579/Molecular testing is essential for guiding treatment in non-small cell lung cancer (NSCLC), but community practices often face significant barriers that can delay results and care. From limited biopsy samples and logistical hurdles to insurance restrictions, these challenges can slow access to next-Understanding Sebopsoriasis: Navigating the Clinical Overlap of Dermatoses
https://reachmd.com/programs/dermconsult/understanding-sebopsoriasis-navigating-the-clinical-overlap-of-dermatoses/36373/Sebopsoriasis—where features of seborrheic dermatitis and psoriasis converge—remains a diagnostic gray area in dermatology. In this expert-led discussion, Dr. Raj Chovatiya explores the clinical nuances, distinguishing features, and immunologic overlap of these conditions. Dr. Chovatiya is aAdvancing Noninvasive CRC Screening: Exploring an Aptamer-Based Assay
https://reachmd.com/programs/project-oncology/advancing-noninvasive-crc-screening-exploring-an-aptamer-based-assay/36407/With one in three eligible Americans still unscreened for colorectal cancer (CRC), there’s an urgent need for noninvasive and affordable alternatives to colonoscopy. A 2025 study published in ACS Sensors introduces a novel aptamer-based colorimetric assay that targets Parvimonas micra—a gut microbeAnalyzing Safety Data From Level Up
https://reachmd.com/series/the-practical-dermatology-podcast/analyzing-safety-data-from-level-up/33944/The latest news and updates, plus Matthew Zirwas, MD, FAAD, joins Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, to discuss the importance of the Week 16 safety data from the Level Up study on upadacitinib. Silverberg JI, Bunick CG, et al. Efficacy and safety of upadacitinib versuUncovering the Burden of Childhood Food Allergies: Key Findings from a Survey
https://reachmd.com/programs/frontlines-food-allergies/uncovering-the-burden-of-childhood-food-allergies-key-findings-from-a-survey/26315/Here are the findings from a survey that uncovered the burden of childhood food allergies, including its prevalence, severity, and age distribution.Angiotensinogen RNAi therapeutic lowers blood pressure in combination with standard antihypertensive
https://reachmd.com/programs/acc-action-center/angiotensinogen-rnai-therapeutic-lowers-blood-pressure-in-combination-with-standard-antihypertensive/24337/ACC.24 - Akshay Desai shares the findings of the phase 2 KARDIA-2 trial. “Treatment with zilebesiran seems to be an effective therapy to incrementally reduce blood pressure in patients with mild-to-moderate hypertension despite treatment with indapamide, amlodipine or olmesartan”, says Akshay Desai.